Primary care and emergency medicine clinicians should familiarize themselves with common ophthalmologic conditions that, with timely referral and treatment, may help to improve vision. Ischemic optic ...
The use of semaglutide, a glucagon-like peptide 1 receptor agonist (GLP-1 RA), is not associated with an increased risk for nonarteritic anterior ischemic optic neuropathy (NAION) in patients with ...
Patients treated with glucagon-like peptide 1 receptor agonists (GLP-1 RAs) appear to have a very low incidence of nonarteritic anterior ischemic optic neuropathy (NAION) when appropriately prescribed ...
Semaglutide exposure was significantly associated with a higher incidence rate and independently predicted a higher risk for upcoming nonarteritic anterior ischemic optic neuropathy. HealthDay News — ...
A potentially blinding condition is a very rare side effect of the GLP-1 receptor agonist semaglutide (Ozempic, Wegovy, Rybelsus), the European Medicines Agency (EMA) concluded. Following a review of ...
A novel gene therapy that leads to cellular rejuvenation could restore vision after non-arteritic anterior ischemic optic neuropathy (NAION) and glaucoma. The technique is based on a reprogramming ...
The study found a median of 3.3 years between the initiation of GLP-1 RA use and the incidence of NAION. An increased risk for NAION was seen in association with 2 GLP-1 RAs: hazard ratios, 1.39 for ...
About The Study: The findings of this study suggest an association between semaglutide, a glucagon-like peptide 1 receptor agonist, and nonarteritic anterior ischemic optic neuropathy. As this was an ...
Increased risk for NAION seen among participants with T2D, overweight/obesity receiving semaglutide vs non-GLP1-RA meds. HealthDay News — Semaglutide is associated with nonarteritic anterior ischemic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback